Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226871 · ClinicalTrials.gov registry record · Phase 2
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
A Phase 2 study of Breast Cancer and Head and Neck Cancer, sponsored by Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 20
- Study locations
NCT05226871: Active Phase 2 study of Breast Cancer and Head and Neck Cancer, sponsored by Pfizer.
NCT05226871 is a Phase 2 study of Breast Cancer and Head and Neck Cancer that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 35 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05226871, a Phase 2 study of Breast Cancer and Head and Neck Cancer, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Cetuximab
- DRUG Fulvestrant
- DRUG Palbociclib
Study Locations (20)
Other
- Cancer Hospital Chinese Academy of Medical Science - Beijing
- Seoul National University Hospital - Seoul
- National Cheng Kung University Hospital - Tainan
- Mackay Memorial Hospital - Taipei
- Department of Medicine, Faculty of Medicine Siriraj Hospital - Bangkok
Liaoning
- Liaoning Cancer Hospital and Institute - Shenyang
- The First Hospital of China Medical University - Shenyang
California
- UCSF Medical Center at Mission Bay - San Francisco
Anhui
- The First Affiliated Hospital of Anhui Medical University - Hefei
Beijing Municipality
- Beijing Cancer Hospital - Beijing
Guangdong
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University - Guangzhou
Heilongjiang
- Harbin Medical University Cancer Hospital - Harbin
Henan
- Henan Cancer Hospital - Zhengzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05226871 still lists
NCT05226871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Letrozole is the first listed.
NCT05226871 names 20 study sites across 15 states, led by Other, Liaoning, California.
Frequently Asked Questions
What is clinical trial NCT05226871 about?
NCT05226871 is a clinical study titled "Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies". The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproduc...
What is the current status of trial NCT05226871?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-07-07. Estimated completion is 2026-12-31.
What conditions does trial NCT05226871 study?
This clinical trial studies the following conditions: Breast Cancer, Head and Neck Cancer.
What interventions are being tested in trial NCT05226871?
The interventions under investigation include: Letrozole (DRUG), Cetuximab (DRUG), Fulvestrant (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT05226871?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05226871 being conducted?
This trial has 20 study locations across California, Anhui, Beijing Municipality, Guangdong, Heilongjiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05226871's enrollment target sits among peer trials
35 922nd of 1224 higher than 298 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI